Accuracy of brain natriuretic peptide and N-terminal brain natriuretic peptide for detecting paediatric pulmonary hypertension: a systematic review and meta-analysis

References

• Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1–12. doi: 10.1001/jama.2022.4402.
   Web of Science ®Google Scholar
• Jin N, Yu M, Du X, et al. Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics. BMC Cardiovasc Disord. 2023;23(1):167. doi: 10.1186/s12872-023-03171-5.
   PubMed Web of Science ®Google Scholar
• Abman SH, Mullen MP, Sleeper LA, et al. Characterisation of pediatric pulmonary hypertensive vascular disease from the PPHNet registry. Eur Respir J. 2021;59(1):2003337. doi: 10.1183/13993003.03337-2020.
   PubMed Web of Science ®Google Scholar
• Li L, Zhu X, Chen X, et al. Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr. 2023;182(5):2067–2076. doi: 10.1007/s00431-022-04750-y.
   PubMed Web of Science ®Google Scholar
• Sawada H, Mitani Y, Nakayama T, et al. Detection of pediatric pulmonary arterial hypertension by school electrocardiography mass screening. Am J Respir Crit Care Med. 2019;199(11):1397–1406. doi: 10.1164/rccm.201802-0375OC.
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916. doi: 10.1183/13993003.01916-2018.
   PubMed Web of Science ®Google Scholar
• van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in The Netherlands. Epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755–1764. doi: 10.1161/CIRCULATIONAHA.110.969584.
   PubMed Web of Science ®Google Scholar
• Lammers AE, Apitz C, Zartner P, et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The european paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart. 2016;102 Suppl 2:ii1–13. doi: 10.1136/heartjnl-2015-307792.
   PubMed Web of Science ®Google Scholar
• Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D117–26. doi: 10.1016/j.jacc.2013.10.028.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Fretheim H, Midtvedt Ø, et al. Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. Rheumatology (Oxford). 2018;57(3):480–487. doi: 10.1093/rheumatology/kex435.
   PubMed Web of Science ®Google Scholar
• O’Byrne ML, Kennedy KF, Kanter JP, et al. Risk factors for major early adverse events related to cardiac catheterization in children and young adults with pulmonary hypertension: an analysis of data from the IMPACT (improving adult and congenital treatment) registry. J Am Heart Assoc. 2018;7:e008142.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Bettermann E, Kelleman M, et al. N-terminal pro-B-type-natriuretic peptide as a screening tool for pulmonary hypertension in the paediatric population. Cardiol Young. 2021;31(10):1595–1607. doi: 10.1017/S1047951121000585.
   PubMed Web of Science ®Google Scholar
• Hansmann G. Pulmonary hypertension in infants, children, and young adults. J Am Coll Cardiol. 2017;69(20):2551–2569. doi: 10.1016/j.jacc.2017.03.575.
   PubMed Web of Science ®Google Scholar
• Volpe M, Gallo G, Rubattu S. Endocrine functions of the heart: from bench to bedside. Eur Heart J. 2023;44(8):643–655. doi: 10.1093/eurheartj/ehac759.
   PubMed Web of Science ®Google Scholar
• Nova R, Putra ST, Nurmaini S, et al. The association between NTproBNP biomarker levels and clinical symptoms of cardiac septal defects in children. Open Access Maced J Med Sci. 2022;10(B):1047–1051. doi: 10.3889/oamjms.2022.8531.
   Google Scholar
• Tufekci S, Kizilca O, Aygun E. N-terminal prohormone of brain natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension in newborns. J Ist Faculty Med. 2022;85:228–235.
   Google Scholar
• Zhang H, Sun T, Yang J, et al. Lipocalin 2: could it be a new biomarker in pediatric pulmonary hypertension associated with congenital heart disease? Rev Cardiovasc Med. 2021;22(2):531–536. doi: 10.31083/j.rcm2202061.
   PubMed Web of Science ®Google Scholar
• Griffiths M, Yang J, Everett AD, et al. Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants. J Perinatol. 2020;40(11):1625–1633. doi: 10.1038/s41372-020-0671-8.
   PubMed Web of Science ®Google Scholar
• Naeem B, Ayub A, Aly AM, et al. Urinary NT-proBNP as a potential noninvasive biomarker for screening of pulmonary hypertension in preterm infants: a pilot study. J Perinatol. 2020;40(4):628–632. doi: 10.1038/s41372-019-0581-9.
   PubMed Web of Science ®Google Scholar
• Behere S, Alapati D, McCulloch MA. Screening echocardiography and brain natriuretic peptide levels predict late pulmonary hypertension in infants with bronchopulmonary dysplasia. Pediatr Cardiol. 2019;40(5):973–979. doi: 10.1007/s00246-019-02100-8.
   PubMed Web of Science ®Google Scholar
• Avitabile CM, Ansems S, Wang Y, et al. Accuracy of brain natriuretic peptide for diagnosing pulmonary hypertension in severe bronchopulmonary dysplasia. Neonatology. 2019;116(2):147–153. doi: 10.1159/000499082.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez M, Benavente-Fernandez I, Castellano-Martinez A, et al. NT-proBNP plasma levels as biomarkers for pulmonary hypertension in healthy infants with respiratory syncytial virus infection. Biomark Med. 2019;13(8):605–618. doi: 10.2217/bmm-2018-0348.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Aly AM, Malloy MH, et al. NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol. 2018;38(9):1252–1257. doi: 10.1038/s41372-018-0164-1.
   PubMed Web of Science ®Google Scholar
• Pektaş A, Olguntürk R, Kula S, et al. Biomarker and shear stress in secondary pediatric pulmonary hypertension. Turk J Med Sci. 2017;47(6):1854–1860. doi: 10.3906/sag-1609-13.
   PubMed Web of Science ®Google Scholar
• Li G, Li Y, Tan X, et al. Plasma growth differentiation factor-15 is a potential biomarker for pediatric pulmonary arterial hypertension associated with congenital heart disease. Pediatr Cardiol. 2017;38(8):1620–1626. doi: 10.1007/s00246-017-1705-7.
   PubMed Web of Science ®Google Scholar
• Li G, Tang L, Jia P, et al. Elevated plasma connective tissue growth factor levels in children with pulmonary arterial hypertension associated with congenital heart disease. Pediatr Cardiol. 2016;37(4):714–721. doi: 10.1007/s00246-015-1335-x.
   PubMed Web of Science ®Google Scholar
• Montgomery AM, Bazzy-Asaad A, Asnes JD, et al. Biochemical screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Neonatology. 2016;109(3):190–194. doi: 10.1159/000442043.
   PubMed Web of Science ®Google Scholar
• Cuna A, Kandasamy J, Fineberg N. B-type natriuretic pep- tide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatol. 2013;3:33–36.
   Google Scholar
• Reynolds EW, Ellington JG, Vranicar M, et al. Brain- type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics. 2004;114(5):1297–1304. doi: 10.1542/peds.2004-0525.
   PubMed Web of Science ®Google Scholar
• Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003;45(3):249–254. doi: 10.1046/j.1442-200x.2003.01716.x.
   PubMed Web of Science ®Google Scholar
• McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–396. doi: 10.1001/jama.2017.19163.
   PubMed Web of Science ®Google Scholar
• Salameh JP, Bossuyt PM, McGrath TA, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632. doi: 10.1136/bmj.m2632.
   PubMedGoogle Scholar
• Abman SH, Ivy DD, Archer SL, et al. Ediatric pulmonary hypertension: guidelines from the American heart association and American thoracic society. Am J Respir Crit Care Med. 2016;194(7):898–906. doi: 10.1164/rccm.201606-1183ST.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536. doi: 10.7326/0003-4819-155-8-201110180-00009.
   PubMed Web of Science ®Google Scholar
• Qiu X, Tang Y, Yue Y, et al. Accuracy of interferon-γ-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(6):667–672. doi: 10.1016/j.cmi.2018.12.006.
   PubMed Web of Science ®Google Scholar
• Baker AM, Hsu FC, Gayzik FS. A method to measure predictive ability of an injury risk curve using an observation-adjusted area under the receiver operating characteristic curve. J Biomech. 2018;72:23–28. doi: 10.1016/j.jbiomech.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wang H, Tang Y, et al. Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis. Ann Med. 2020;52(7):376–385. doi: 10.1080/07853890.2020.1800073.
   PubMed Web of Science ®Google Scholar
• Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865–2884. doi: 10.1002/sim.942.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was ­assessed. J Clin Epidemiol. 2005;58(9):882–893. doi: 10.1016/j.jclinepi.2005.01.016.
   PubMed Web of Science ®Google Scholar
• Gallo G, Rubattu S, Autore C, et al. Natriuretic peptides: it is time for guided therapeutic strategies based on their molecular mechanisms. Int J Mol Sci. 2023;24(6):5131. doi: 10.3390/ijms24065131.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qin D, Qin L, et al. Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: a systematic review and meta-analysis. Joint Bone Spine. 2022;89(2):105287. doi: 10.1016/j.jbspin.2021.105287.
   PubMed Web of Science ®Google Scholar
• Ten Kate CA, Tibboel D, Kraemer US. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr. 2015;174(10):1267–1275. doi: 10.1007/s00431-015-2619-0.
   PubMed Web of Science ®Google Scholar
• Taylor KS, Verbakel JY, Feakins BG, et al. Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. BMJ. 2018;361:k1450. doi: 10.1136/bmj.k1450.
   PubMedGoogle Scholar
• Bettencourt PM. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart. 2005;91(11):1489–1494. doi: 10.1136/hrt.2005.063784.
   PubMed Web of Science ®Google Scholar